Skip to search formSkip to main contentSkip to account menu

SB 207499

Known as: SB-207499 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Cilomilast

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast
Phosphodiesterase-4 (PDE4) is an important cAMP-metabolising enzyme in immune and inflammatory cells, airway smooth muscle and… 
Review
2006
Review
2006
[Current and future approaches for the treatment of inflammatory diseases of inferior respiratory tract].
Among the allergic disorders we emphasize the inflammatory diseases of the inferior respiratory tract by their incidence… 
2002
2002
In vitro PKA phosphorylation‐mediated human PDE4A4 activation
2002
2002
Benefit of phosphodiesterase 4 inhibitors as supplemental therapy after lung transplantation concerning their antiproliferative effects: an experimental study using a heterotopic rodent model
Background. Recent advances in the understanding of immunomodulatory properties of phosphodiesterase 4 (PDE4) inhibitors… 
2000
2000
PDE inhibitors--Second William Harvey Research Conference. Drugs with an expanding range of therapeutic uses. 1-3 December 1999, Nice, France.
  • T. Torphy
  • IDrugs : the investigational drugs journal
  • 2000
  • Corpus ID: 30380859
This meeting underscored advances in the exploitation of cyclic nucleotide phosphodiesterases (PDEs) as drug targets. One… 
Review
1999
Review
1999
Therapeutic potential of phosphodiesterase 4 inhibitors in allergic diseases.
Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease… 
1999
1999
Ariflo (SmithKline Beecham plc).
  • W. Brown
  • IDrugs : the investigational drugs journal
  • 1999
  • Corpus ID: 41061044
Ariflo (SB-207499) is a phosphodiesterase (PDE)4 inhibitor under development by SmithKline Beecham and in phase III and II… 
Highly Cited
1998
Highly Cited
1998
Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.
We evaluated the airway activity of the novel phosphodiesterase type 4 inhibitor SB 207499 [Ariflo; c-4-cyano-4-(3-cyclopentyloxy… 
1997
1997
Phosphodiesterase inhibitors: the next generation
Phosphodiesterase type IV (PDE IV) inhibitors have wide ranging anti-inflammatory effects which have given rise to the concept… 
1995
1995
Novel PDE IV inhibitors: exploring their potential in asthma
&The enzyme phosphodiesterase (PDE) IV is a target for several companies seeking to develop innovative agents with both anti… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)